Description
Product Usage Information
SignalFlex™ conjugates are produced using highly validated Cell Signaling Technology ® primary antibodies and conjugation methods that have been rigorously tested, ensuring high-quality conjugates and lot-to-lot consistency. These conjugates are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. However, they are not tested on specific assays. Optimal dilutions/concentrations should be determined by the end user. When performing flow cytometry, we recommend using an isotype control conjugate at the same concentration as the antibody conjugate.
Storage
Supplied in PBS (pH 7.2), less than 0.1% sodium azide, and 2 mg/mL BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.
Specificity / Sensitivity
PRAME (E7I1B) Rabbit mAb (SignalFlex™ mFluor™ Violet 510 Conjugate) recognizes endogenous levels of total PRAME protein. Non-specific non-nuclear staining was observed in smooth muscle.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly163 of human PRAME protein.
Background
Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). PRAME (preferentially expressed antigen in melanoma) is a cancer/testis antigen not normally expressed in any tissues except testis, but is upregulated in tumors. PRAME is expressed in melanoma cells and is recognized by cytolytic T-cells (4). It is also upregulated in other diseases, such as synovial sarcoma (5), NSCLC (6), and breast cancer, where it is thought to contribute to tumorigenesis and metastasis (7). PRAME is also highly expressed in liquid tumors such as AML (8) and can be predictive of clinical outcome in some circumstances (9). PRAME and other cancer/testis antigens are currently being pursued as novel immunotherapy targets and diagnostic biomarkers (10).
Alternate Names
cancer/testis antigen 130; CT130; MAPE; Melanoma antigen preferentially expressed in tumors; OIP-4; OIP4; Opa-interacting protein 4; Opa-interacting protein OIP4; PRAME; PRAME nuclear receptor transcriptional regulator; preferentially expressed antigen in melanoma; Preferentially expressed antigen of melanoma
